GuidelineVeterinary dermatology2025
World Association for Veterinary Dermatology Consensus Statement for Diagnosis, and Evidence-Based Clinical Practice Guidelines for Treatment and Prevention of Canine Leishmaniosis.
Guideline in Veterinary dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- LeishVet update and current recommendations on feline leishmaniosis.Parasites & vectors · 2026Review
- Vector-borne pathogens in dogs from different regions of Afghanistan.Parasites & vectors · 2026Article
- Direct quantitative PCR detects genetic biomarkers of antileishmanial drug resistance in clinical samples from dogs with leishmaniosis.BMC veterinary research · 2026Article
- Structural basis of ligand selectivity in FAD/NAD(P)H-dependent dehydrogenases: insights from trypanothione reductase and type II NADH dehydrogenase.Protein science : a publication of the Protein Society · 2026Article
- Targeting of Leishmania proteins by β-Lapachone derivatives reveals a promising multitarget candidate.Archives of microbiology · 2026Article
- Canine Leishmaniasis in Rio de Janeiro, Brazil (2000-2015): Taxonomic Characterisation of Etiological Agents and Geospatial Case Analysis.Zoonoses and public health · 2026Article
- Updated Canine Leishmaniosis Working Group recommendations for leishmaniosis in dogs: Q&A on clinical management.Parasites & vectors · 2026Review
- Development and Validation of a New Scoring System (Total Leishmania Score) for Dogs withPathogens (Basel, Switzerland) · 2026Article
- Leishmania infantum in red foxes (Vulpes vulpes): from clinical findings to cytokine expression.Parasites & vectors · 2026Article
- Ocular Involvement as a Key Marker of Systemic Disease in Dogs Naturally Infected withPathogens (Basel, Switzerland) · 2026Article
- Article
- Autochthonous canine cutaneous leishmaniasis caused byCurrent research in parasitology & vector-borne diseases · 2026Article
- Importance of Different Parameters for Monitoring Dogs withPathogens (Basel, Switzerland) · 2025Article
- Evaluation of the Repeatability and Reproducibility of the Results of Lymph Node Cytology forVeterinary sciences · 2025Article
- Large-scale randomized double-blind field clinical trial for safety and efficacy assessment of the DNA vaccine Neoleish against canine leishmaniasis.PLoS neglected tropical diseases · 2025Article
- StandardizedVeterinary sciences · 2025Article
- Emergence of autochthonousFrontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCanine leishmaniosis (CanL) due to Leishmania infantum remains common, and veterinarians do not always follow scientifically sound approaches for diagnosis, treatment and prevention.
objectivesTo provide consensus guidelines for diagnosis and evidence-based guidelines for treatment and prevention of CanL. METHODS AND MATERIAL: Clinical consensus guidelines for the diagnosis were structured based on literature and authors' experience. Three electronic databases were searched for randomised controlled trials, systematic reviews and meta-analyses on treatment and prevention. RESULTS, CONCLUSIONS AND CLINICAL IMPORTANCE: Diagnosis should be based on compatible clinical signs and/or clinicopathologic abnormalities, exclusion of differentials, demonstration of infection and increased concentration of anti-Leishmania IgG (quantitative serology). Euthanasia for public health purposes is not recommended and drugs with anti-Leishmania activity should be avoided in subclinically infected dogs. Recommended treatments include meglumine antimoniate-allopurinol (first-line treatment), miltefosine-allopurinol (first-line treatment) and aminosidine-allopurinol (second-line treatment); marbofloxacin may be considered in dogs with advanced chronic kidney disease. In endemic areas, recommended measures for prevention include deltamethrin 4% collar, flumethrin 4.5%-imidacloprid 10% collar or permethrin 50%-imidacloprid 10% spot-on, not using infected blood products for transfusion, not breeding seropositive bitches or dogs with CanL, administration of domperidone (seronegative dogs) and dietary nucleotides-active hexose correlated compound (subclinically infected, seropositive dogs). Vaccination with LiESP with MDP may be considered, whereas protein Q vaccine is recommended in areas with very high rates of seroconversion. In non-endemic areas, recommended measures include not using infected blood products for transfusion and removal of infected female dogs from reproduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.